

=> fil cap
FILE 'CAPLUS' ENTERED AT 15:26:14 ON 26 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 26 Nov 2008 VOL 149 ISS 22
FILE LAST UPDATED: 25 Nov 2008 (20081125/ED)


Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> d que 19
L1 STR





Page 2-A

VAR G1=23-2 25-3/25-2 23-3/18-2 22-3

REP G2=(0-2) A

REP G4=(0-2) CH2

REP G5=(0-6) A

VAR G6=ME/CL

VAR G7=30/33

VAR G8=H/37/CF3/38/39/41/42/44/56

VAR G9=H/ME/X

VAR G10=NH2/57

VAR G11=37/38/59/62/44/41/66/68

VAR G12=38/59/62/44/41

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 8

CONNECT IS E1 RC AT 37

CONNECT IS E1 RC AT 38

CONNECT IS E2 RC AT 39

CONNECT IS E1 RC AT 40

CONNECT IS E1 RC AT 64

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 27

GGCAT IS UNS AT 29

GGCAT IS SAT AT 37

GGCAT IS SAT AT 38

GGCAT IS LIN SAT AT 39

GGCAT IS SAT AT 40

GGCAT IS UNS AT 41

GGCAT IS UNS AT 43

GGCAT IS SAT AT 64

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS X2 C AT 39


GRAPH ATTRIBUTES:

RSPEC 44 50

NUMBER OF NODES IS 70

STEREO ATTRIBUTES: NONE

L2 STR




VAR G1=ME/CL
 REP G4=(0-2) CH2
 NODE ATTRIBUTES:
 CONNECT IS E2 RC AT 3
 DEFAULT MLEVEL IS ATOM
 GGCAT IS PCY UNS AT 8
 GGCAT IS UNS AT 10
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 2
 NUMBER OF NODES IS 10


STEREO ATTRIBUTES: NONE

L3 SCR 7 OR 21
 L4 331 SEA FILE=REGISTRY SSS FUL L3 AND L2 AND L1
 L6 STR



71 72

Page 1-A



Page 2-A

VAR G6=ME/CL
 VAR G7=30/33
 VAR G8=H/37/CF3/38/39/41/42/44/56
 VAR G9=H/ME/X
 VAR G10=NH2/57
 VAR G11=37/38/59/62/44/41/66/68
 VAR G12=38/59/62/44/41
NODE ATTRIBUTES:
 CONNECT IS E2 RC AT 8
 CONNECT IS E1 RC AT 37
 CONNECT IS E1 RC AT 38
 CONNECT IS E2 RC AT 39
 CONNECT IS E1 RC AT 40
 CONNECT IS E1 RC AT 64
 DEFAULT MLEVEL IS ATOM
 GGCAT IS SAT AT 37
 GGCAT IS SAT AT 38
 GGCAT IS LIN SAT AT 39
 GGCAT IS SAT AT 40
 GGCAT IS UNS AT 41
 GGCAT IS UNS AT 43
 GGCAT IS SAT AT 64
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS X2 C AT 39

GRAPH ATTRIBUTES:

RSPEC 44 50
 NUMBER OF NODES IS 60

STEREO ATTRIBUTES: NONE

L8 128 SEA FILE=REGISTRY SUB=L4 SSS FUL L6
 L9 4 SEA FILE=CAPLUS ABB=ON PLU=ON L8

=> fil wpix
 FILE 'WPIX' ENTERED AT 15:26:39 ON 26 NOV 2008
 COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED: 21 NOV 2008 <20081121/UP>
 MOST RECENT UPDATE: 200875 <200875/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
 >>> Now containing more than 1.2 million chemical structures in DCR <<

>>> IPC Reform backfile reclassifications have been loaded to end of September 2008. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC, and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC, 20071130/UPIC, 20080401/UPIC, 20080701/UPIC and 20081001/UPIC.
 ECLA reclassifications to mid August and US national classification mid September 2008 have also been loaded. Update dates 20080401, 20080701 and 20081001/UPEC and /UPNC have been assigned to these. <<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/>


EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:

http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0608.pdf

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

=> d que 119

L1 STR




45

51

61

65

Page 1-A



Page 2-A

VAR G1=23-2 25-3/25-2 23-3/18-2 22-3

REP G2=(0-2) A

REP G4=(0-2) CH2

REP G5=(0-6) A

VAR G6=ME/CL

VAR G7=30/33

VAR G8=H/37/CF3/38/39/41/42/44/56

VAR G9=H/ME/X

VAR G10=NH2/57

VAR G11=37/38/59/62/44/41/66/68

VAR G12=38/59/62/44/41

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 8

CONNECT IS E1 RC AT 37


CONNECT IS E1 RC AT 38
 CONNECT IS E2 RC AT 39
 CONNECT IS E1 RC AT 40
 CONNECT IS E1 RC AT 64
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 27
 GGCAT IS UNS AT 29
 GGCAT IS SAT AT 37
 GGCAT IS SAT AT 38
 GGCAT IS LIN SAT AT 39
 GGCAT IS SAT AT 40
 GGCAT IS UNS AT 41
 GGCAT IS UNS AT 43
 GGCAT IS SAT AT 64
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS X2 C AT 39

GRAPH ATTRIBUTES:

RSPEC 44 50
 NUMBER OF NODES IS 70

STEREO ATTRIBUTES: NONE

L2 STR




VAR G1=ME/CL
 REP G4=(0-2) CH2
 NODE ATTRIBUTES:
 CONNECT IS E2 RC AT 3
 DEFAULT MLEVEL IS ATOM
 GGCAT IS PCY UNS AT 8
 GGCAT IS UNS AT 10
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RSPEC 2
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
 L6 STR



71 72

Page 1-A



Page 2-A

VAR G6=ME/CL
 VAR G7=30/33
 VAR G8=H/37/CF3/38/39/41/42/44/56
 VAR G9=H/ME/X
 VAR G10=NH2/57
 VAR G11=37/38/59/62/44/41/66/68
 VAR G12=38/59/62/44/41

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 8
 CONNECT IS E1 RC AT 37
 CONNECT IS E1 RC AT 38
 CONNECT IS E2 RC AT 39
 CONNECT IS E1 RC AT 40
 CONNECT IS E1 RC AT 64
 DEFAULT MLEVEL IS ATOM
 GGCAT IS SAT AT 37
 GGCAT IS SAT AT 38
 GGCAT IS LIN SAT AT 39

GGCAT IS SAT AT 40
 GGCAT IS UNS AT 41
 GGCAT IS UNS AT 43
 GGCAT IS SAT AT 64
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS X2 C AT 39

GRAPH ATTRIBUTES:

RSPEC 44 50
 NUMBER OF NODES IS 60

STEREO ATTRIBUTES: NONE

L18 103 SEA FILE=WPIX SSS FUL L1 AND L2 AND L6
 L19 3 SEA FILE=WPIX ABB=ON PLU=ON L18/DCR

=> dup rem 19 119

FILE 'CAPLUS' ENTERED AT 15:26:47 ON 26 NOV 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 15:26:47 ON 26 NOV 2008

COPYRIGHT (C) 2008 THOMSON REUTERS
 PROCESSING COMPLETED FOR L9
 PROCESSING COMPLETED FOR L19

L22 4 DUP REM L9 L19 (3 DUPLICATES REMOVED)
 ANSWERS '1-4' FROM FILE CAPLUS

=> d l22 ibib abs hitstr tot


L22 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2007:14480 CAPLUS Full-text
 DOCUMENT NUMBER: 146:121821
 TITLE: Preparation of bicyclic derivatives as p38 kinase inhibitors
 INVENTOR(S): Almansa Rosales, Carmen; Virgili Bernado, Marina
 PATENT ASSIGNEE(S): J. Uriach y Compania S.A., Spain
 SOURCE: PCT Int. Appl., 80pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007000339	A1	20070104	WO 2006-EP6255	20060628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

AU 2006263961	A1 20070104	AU 2006-263961	20060628
CA 2613720	A1 20070104	CA 2006-2613720	20060628
EP 1917241	A2 20080507	EP 2006-776093	20060628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, RS			
NO 2007005987	A 20080111	NO 2007-5987	20071123
MX 200715531	A 20080306	MX 2007-15531	20071207
KR 2008028870	A 20080402	KR 2007-729139	20071213
CN 101208301	A 20080625	CN 2006-80023005	20071226
IN 2007CN06046	A 20080613	IN 2007-CN6046	20071231
PRIORITY APPLN. INFO.: :		EP 2005-380140	A 20050629
		WO 2006-EP6255	W 20060628

OTHER SOURCE(S): MARPAT 146:121821

GI




AB Title compds. represented by the formula I [wherein A = CR₁R₂ or NR₃; R₁, R₂ = alkyl; R₃, R₈ = independently -(CH₂)_p-Cyl or (un)substituted alkyl; m = 1 or 2; R₄ = -B-R₈; R₅ = H, halo, alkyl or alkoxy; R₆ = halo or Me; p = 0-2; Cyl = (un)substituted Ph, heteroaryl, cycloalkyl or heterocyclyl; B = -CONR₉- or -NR₉CO- or -NR₉CONR₉-; R₉ = H or alkyl; or salts thereof] were prepared as p38 kinase inhibitors. For example, II was provided in a multi-step synthesis starting from 4-bromo-2-methylbenzoic acid. I showed more than 50 % inhibition for p38 α enzyme activity at 10 μ M. Thus, I are useful for the treatment of p38 kinase mediated diseases, such as immune diseases.

IT 918332-35-1P, N-Cyclopropyl-4-methyl-3-[2-(3-nitrobenzyl)-1-oxo-2,3-dihydroisoindolin-5-yl]benzamide 918332-61-3P,
3-[2-(3-Aminobenzyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-N-cyclopropyl-4-methylbenzamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of bicyclic derivs. as p38 kinase inhibitors)


RN 918332-35-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-[(3-nitrophenyl)methyl]-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-61-3 CAPLUS

CN Benzamide, 3-[2-[(3-aminophenyl)methyl]-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)




IT 918332-99-4P, N-Cyclopropyl-4-methyl-3-(1-oxo-2-phenyl-2,3-dihydroisoindolin-5-yl)benzamide 918332-00-0P,
 N-(Cyclopropylmethyl)-4-methyl-3-(1-oxo-2-phenyl-2,3-dihydroisoindolin-5-yl)benzamide 918332-01-1P,
 3-(2-Benzyl-1-oxo-2,3-dihydroisoindolin-5-yl)-N-cyclopropyl-4-methylbenzamide 918332-02-2P,
 3-(2-Benzyl-1-oxo-2,3-dihydroisoindolin-5-yl)-N-(cyclopropylmethyl)-4-methylbenzamide 918332-07-7P,
 N-Cyclopropyl-3-[2-(2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-08-8P,
 N-Cyclopropyl-3-[2-(2-hydroxy-5-sulfamoylphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-09-9P,
 N-Cyclopropyl-3-[2-(3-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-10-2P,
 N-Cyclopropyl-3-[2-(2-hydroxy-6-methylphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-11-3P,
 N-Cyclopropyl-4-methyl-3-[1-oxo-2-(thiazol-2-yl)-2,3-dihydroisoindolin-5-yl]benzamide 918332-12-4P,
 N-Cyclopropyl-3-[2-(4-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-13-5P,
 4-Chloro-N-cyclopropyl-3-[2-(2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]benzamide 918332-14-6P,
 N-Cyclopropyl-3-[2-(5-chloro-2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-15-7P,
 N-Cyclopropyl-3-[2-(4-chloro-2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-34-0P,
 N-Cyclopropyl-4-methyl-3-[1-oxo-2-(pyridin-4-yl)methyl]-2,3-dihydroisoindolin-5-yl]benzamide 918332-36-2P,
 3-[2-(3-Cyanophenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-N-cyclopropyl-4-methylbenzamide 918332-37-3P,
 N-Cyclopropyl-4-methyl-3-[2-(3-morpholin-4-yl)phenyl]-1-oxo-2,3-dihydroisoindolin-5-yl]benzamide 918332-38-4P,
 3-[2-(Biphenyl-3-yl)-1-oxo-2,3-dihydroisoindolin-5-yl]-N-cyclopropyl-4-

methylbenzamide 918332-41-9P,
 N-Cyclopropyl-4-methyl-3-[1-oxo-2-[2-(pyridin-3-yl)ethyl]-2,3-dihydroisoindolin-5-yl]benzamide 918332-42-0P,
 N-Cyclopropyl-3-[2-(indazol-6-yl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-43-1P,
 N-Cyclopropyl-3-[2-(indol-5-yl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-45-3P,
 N-Cyclopropyl-3-[2-(6-methoxypyridin-3-yl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-47-5P,
 N-Cyclopropyl-3-[2-(2-methoxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-48-6P,
 N-Cyclopropyl-5-fluoro-3-[2-(2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-50-0P,
 2-Cyclopropyl-N-[4-methyl-3-(1-oxo-2-phenyl-2,3-dihydroisoindolin-5-yl)phenyl]acetamide 918332-52-2P,
 N-[4-Methyl-3-(1-oxo-2-phenyl-2,3-dihydroisoindolin-5-yl)phenyl]furan-3-carboxamide 918332-62-4P,
 N-Cyclopropyl-3-[2-[3-[(methylsulfonyl)amino]benzyl]-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic derivs. as p38 kinase inhibitors)


RN 918331-99-4 CAPLUS

CN Benzamide, N-cyclopropyl-3-(2,3-dihydro-1-oxo-2-phenyl-1H-isoindol-5-yl)-4-methyl- (CA INDEX NAME)




RN 918332-00-0 CAPLUS

CN Benzamide, N-(cyclopropylmethyl)-3-(2,3-dihydro-1-oxo-2-phenyl-1H-isoindol-5-yl)-4-methyl- (CA INDEX NAME)




RN 918332-01-1 CAPLUS


CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-1-oxo-2-(phenylmethyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-02-2 CAPLUS
 CN Benzamide, N-(cyclopropylmethyl)-3-[2,3-dihydro-1-oxo-2-(phenylmethyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-07-7 CAPLUS
 CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(2-hydroxyphenyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-08-8 CAPLUS
 CN Benzamide, 3-[2-[5-(aminosulfonyl)-2-hydroxyphenyl]-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)




RN 918332-09-9 CAPLUS
 CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(3-hydroxyphenyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-10-2 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(2-hydroxy-6-methylphenyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-11-3 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-1-oxo-2-(2-thiazolyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-12-4 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(4-hydroxyphenyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-13-5 CAPLUS


CN Benzamide, 4-chloro-N-cyclopropyl-3-[2,3-dihydro-2-(2-hydroxyphenyl)-1H-isoindol-5-yl]- (CA INDEX NAME)




RN 918332-14-6 CAPLUS
 CN Benzamide, 3-[2-(5-chloro-2-hydroxyphenyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)




RN 918332-15-7 CAPLUS
 CN Benzamide, 3-[2-(4-chloro-2-hydroxyphenyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 918332-34-0 CAPLUS
 CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-1-oxo-2-(4-pyridinylmethyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-36-2 CAPLUS
 CN Benzamide, 3-[2-(3-cyanophenyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)




RN 918332-37-3 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-[3-(4-morpholinyl)phenyl]-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-38-4 CAPLUS

CN Benzamide, 3-(2-[1,1'-biphenyl]-3-yl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl-N-cyclopropyl-4-methyl- (CA INDEX NAME)




RN 918332-41-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-1-oxo-2-[2-(3-pyridinyl)ethyl]-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-42-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(1H-indazol-6-yl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-43-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(1H-indol-5-yl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-45-3 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(6-methoxy-3-pyridinyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-47-5 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(2-methoxyphenyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)




RN 918332-48-6 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(2-hydroxyphenyl)-1-oxo-1H-isoindol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 918332-50-0 CAPLUS

CN Cyclopropaneacetamide, N-[3-(2,3-dihydro-1-oxo-2-phenyl-1H-isoindol-5-yl)-4-methylphenyl]- (CA INDEX NAME)




RN 918332-52-2 CAPLUS

CN 3-Furancarboxamide, N-[3-(2,3-dihydro-1-oxo-2-phenyl-1H-isoindol-5-yl)-4-methylphenyl]- (CA INDEX NAME)



RN 918332-62-4 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-[[3-[(methylsulfonyl)amino]phenyl]methyl]-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:732641 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:211908
 TITLE: Preparation of fused heteroaryl derivatives as p38 kinase inhibitors
 INVENTOR(S): Patel, Vipulkumar Kantibhai; Swanson, Stephen
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073217	A1	20050811	WO 2005-GB266	20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1709028	A1	20061011	EP 2005-702023	20050127
EP 1709028	B1	20081105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007519693	T	20070719	JP 2006-550295	20050127
US 20070054942	A1	20070308	US 2006-587613	20060728
PRIORITY APPLN. INFO.:			GB 2004-2138	A 20040130
			WO 2005-GB266	W 20050127

OTHER SOURCE(S): CASREACT 143:211908; MARPAT 143:211908
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring, R1 = Me or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H, cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo] and their pharmaceutically acceptable salts, are prepared and disclosed as p38 kinase inhibitors. Thus, e.g., II was prepared by palladium catalyzed coupling of 6-bromo-5-fluoro-3-(4-pyridinyl)-1H-indazole (preparation given) with N-cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide. The activity of I was evaluated in fluorescence anisotropy kinase binding assays and it was revealed that compds. of the invention displayed IC50 values of <10 µM or pKi values of >6. I as p38 kinase inhibitor should prove useful in the treatment of disease states mediated by p38 kinase. Pharmaceutical compns. comprising I are disclosed.

IT 862098-61-1P 862098-63-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of fused heteroaryl derivs. as p38 kinase inhibitors)


RN 862098-61-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[5-fluoro-3-(4-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 862098-63-3 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-5-[5-fluoro-3-(4-pyridinyl)-1,2-benzisoxazol-6-yl]-4-methyl- (CA INDEX NAME)



IT 862098-62-2P 862098-64-4P 862098-65-5P


862098-66-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)


RN 862098-62-2 CAPLUS

CN Benzamide, N-cyclopropyl-3-[5-fluoro-3-(1-oxido-4-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 862098-64-4 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-5-[5-fluoro-3-(1-oxido-4-pyridinyl)-1,2-benzisoxazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 862098-65-5 CAPLUS

CN Benzamide, N-ethyl-3-[5-fluoro-3-(6-methoxy-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 862098-66-6 CAPLUS

CN Benzamide, 3-[3-(6-chloro-3-pyridinyl)-5-fluoro-1H-indazol-6-yl]-N-ethyl-4-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2005:729633 CAPLUS Full-text

DOCUMENT NUMBER: 143:211906

TITLE: Preparation of fused heteroaryl derivatives as p38 kinase inhibitors

INVENTOR(S): Bamborough, Paul; Campos, Sebastien Andre; Patel, Vipulkumar Kantibhai; Swanson, Stephen; Walker, Ann Louise

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073189	A1	20050811	WO 2005-GB265	20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1708996	A1	20061011	EP 2005-702022	20050127
EP 1708996	B1	20080827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007519692	T	20070719	JP 2006-550294	20050127
AT 406351	T	20080915	AT 2005-702022	20050127
PRIORITY APPLN. INFO.:			GB 2004-2143	A 20040130
			WO 2005-GB265	W 20050127
OTHER SOURCE(S):	CASREACT 143:211906; MARPAT 143:211906			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring, R1 = Me or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H, cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo] and their pharmaceutically acceptable salts, are prepared and disclosed as p38 kinase inhibitors. Thus, e.g., II was prepared by palladium catalyzed Suzuki coupling of 5-bromo-1-phenyl-1H-indazole (preparation given) with {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid. The activity of I was evaluated in fluorescence anisotropy kinase binding assays and it was revealed that compds. of the invention displayed IC50 values of <10 μM or pKi values of >6. I as p38 kinase inhibitor should prove useful in the treatment of disease states mediated by p38 kinase. Pharmaceutical compns. comprising I are disclosed.

IT 861904-32-7P 861904-72-5P 861904-73-6P
861904-94-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)


RN 861904-32-7 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-72-5 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-pyridinylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-73-6 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(4-pyridinylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-94-1 CAPLUS

CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(2-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)



IT 861904-25-8P 861904-26-9P 861904-27-0P

861904-28-1P 861904-29-2P 861904-30-5P

861904-31-6P 861904-33-8P 861904-34-9P

861904-35-0P 861904-36-1P 861904-37-2P


861904-38-3P 861904-39-4P 861904-40-7P
 861904-41-8P 861904-42-9P 861904-43-0P
 861904-44-1P 861904-45-2P 861904-46-3P
 861904-47-4P 861904-48-5P 861904-49-6P
 861904-50-9P 861904-51-0P 861904-52-1P
 861904-53-2P 861904-54-3P 861904-56-5P
 861904-57-6P 861904-58-7P 861904-59-8P
 861904-60-1P 861904-62-3P 861904-64-5P
 861904-66-7P 861904-67-8P 861904-68-9P
 861904-69-0P 861904-70-3P 861904-71-4P
 861904-75-8P 861904-76-9P 861904-77-0P
 861904-78-1P 861904-79-2P 861904-80-5P
 861904-81-6P 861904-82-7P 861904-83-8P
 861904-84-9P 861904-85-0P 861904-86-1P
 861904-87-2P 861904-88-3P 861904-89-4P
 861904-90-7P 861904-91-8P 861904-92-9P
 861904-93-0P 861904-95-2P 861904-96-3P
 861904-97-4P 861904-98-5P 861904-99-6P
 861905-00-2P 861905-01-3P 861905-02-4P
 861905-03-5P 861905-04-6P 861905-05-7P
 861905-06-8P 861905-07-9P 861905-08-0P
 861905-09-1P 861905-10-4P 861905-11-5P
 861905-12-6P 861905-13-7P 861905-15-9P
 861905-17-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)


RN 861904-25-8 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-26-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 861904-27-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-(4-fluoro-2-methylphenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 861904-28-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-[(4-fluorophenyl)methyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)




RN 861904-29-2 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(4-(trifluoromethyl)phenyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-30-5 CAPLUS


CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-31-6 CAPLUS
 CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(5-methyl-3-isoxazolyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-33-8 CAPLUS
 CN Benzamide, N-cyclopropyl-3-[(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl- (CA INDEX NAME)




RN 861904-34-9 CAPLUS
 CN Benzamide, N-cyclobutyl-3-[(1-(4-fluorophenyl)-1H-indazol-5-yl)-4-methyl- (CA INDEX NAME)



RN 861904-35-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(4-morpholinyl)phenyl]-1H-indazol-5-yl]-(CA INDEX NAME)




RN 861904-36-1 CAPLUS

CN Formic acid, compd. with N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(4-morpholinyl)phenyl]-1H-indazol-5-yl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861904-35-0

CMF C28 H27 F N4 O2



CM 2


CRN 64-18-6

CMF C H2 O2




RN 861904-37-2 CAPLUS

CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-(CA INDEX NAME)




RN 861904-38-3 CAPLUS

CN Benzamide, 3-fluoro-N,4-dimethyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-39-4 CAPLUS

CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-40-7 CAPLUS

CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-propyl- (CA INDEX NAME)




RN 861904-41-8 CAPLUS

CN Benzamide, N-butyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-42-9 CAPLUS

CN Benzamide, N-cyclobutyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-43-0 CAPLUS

CN Benzamide, N-cyclopentyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-44-1 CAPLUS

CN Benzamide, 3-fluoro-4-methyl-N-(1-methylethyl)-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-45-2 CAPLUS

CN Benzamide, N-(cyclopropylmethyl)-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-46-3 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-pyridinyl)-1H-indol-5-yl]- (CA INDEX NAME)




RN 861904-47-4 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-pyridinyl)-1H-indol-5-yl]- (CA INDEX NAME)




RN 861904-48-5 CAPLUS

CN Benzamide, 3-[1-(4-cyanophenyl)-1H-indol-5-yl]-N-cyclopropyl-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-49-6 CAPLUS

CN Benzamide, 3-[1-(3-cyanophenyl)-1H-indol-5-yl]-N-cyclopropyl-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-50-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-51-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(trifluoromethyl)phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-52-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(methylsulfonyl)phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-53-2 CAPLUS

CN Benzeneacetamide, 4-[5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazol-1-yl]-N-methyl- (CA INDEX NAME)



RN 861904-54-3 CAPLUS

CN Benzamide, 3-[1-(4-bromophenyl)-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-56-5 CAPLUS

CN Formic acid, compd. with 3-[1-[4-[(cyclohexylmethyl)amino]phenyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861904-55-4

CMF C31 H33 F N4 O



CM 2


CRN 64-18-6

CMF C H2 O2



RN 861904-57-6 CAPLUS

CN Benzamide, N-cyclopropyl-3-[1-[4-[2-(dimethylamino)ethyl]amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-58-7 CAPLUS

CN Formic acid, compd. with N-cyclopropyl-3-[1-[4-[2-(dimethylamino)ethyl]amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide (2:1) (CA INDEX NAME)

CM 1

CRN 861904-57-6

CMF C28 H30 F N5 O



CM 2


CRN 64-18-6

CMF C H2 O2



RN 861904-59-8 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[(tetrahydro-2H-pyran-4-yl)amino]phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-60-1 CAPLUS

CN Formic acid, compd. with N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[(tetrahydro-2H-pyran-4-yl)amino]phenyl]-1H-indazol-5-yl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861904-59-8

CMF C29 H29 F N4 O2



CM 2

CRN 64-18-6

CMF C H2 O2




RN 861904-62-3 CAPLUS

CN Formic acid, compd. with N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[(tetrahydro-2-furanyl)methyl]amino]phenyl]-1H-indazol-5-yl]benzamide
(1:1) (CA INDEX NAME)

CM 1

CRN 861905-17-1

CMF C29 H29 F N4 O2



CM 2

CRN 64-18-6

CMF C H2 O2




RN 861904-64-5 CAPLUS

CN Formic acid, compd. with N-cyclopropyl-3-fluoro-5-[1-[4-[(2-

methoxyethyl)amino]phenyl]-1H-indazol-5-yl]-4-methylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861904-63-4
CMF C27 H27 F N4 O2



CM 2

CRN 64-18-6
CMF C H2 O2




RN 861904-66-7 CAPLUS

CN Formic acid, compd. with N-cyclopropyl-3-[1-[4-[(3-(dimethylamino)propyl)amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide (2:1) (CA INDEX NAME)

CM 1

CRN 861904-65-6
CMF C29 H32 F N5 O




CM 2

CRN 64-18-6
CMF C H2 O2




RN 861904-67-8 CAPLUS

CN Benzamide, N-cyclopropyl-3-[1-[4-[(2,3-dihydroxypropyl)amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-68-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[1-(2,6-dimethyl-4-pyrimidinyl)-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-69-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-[1-(1,6-dihydro-6-oxo-4-pyrimidinyl)-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861904-70-3 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-5-[3-(4-methoxyphenyl)-1,2-benzisoxazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-71-4 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-5-[3-(4-hydroxyphenyl)-1,2-benzisoxazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-75-8 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-2-pyridinyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-76-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-3-pyridinyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-77-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-4-pyridinyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)




RN 861904-78-1 CAPLUS

CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-2-pyrimidinyl- (CA INDEX NAME)




RN 861904-79-2 CAPLUS

CN Benzamide, 3-fluoro-N-(4-fluorophenyl)-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-80-5 CAPLUS

CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-3-pyridazinyl- (CA INDEX NAME)




RN 861904-81-6 CAPLUS

CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 861904-82-7 CAPLUS

CN Benzamide, N-(4-fluorophenyl)-4-methyl-3-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)




RN 861904-83-8 CAPLUS

CN Benzamide, N-ethyl-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-84-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-85-0 CAPLUS

CN Benzamide, N-ethyl-3-[3-(4-methoxyphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-86-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[3-(4-methoxyphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-87-2 CAPLUS

CN Benzamide, N-ethyl-3-[3-(6-fluoro-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-88-3 CAPLUS

CN Benzamide, 3-[3-(4-ethoxyphenyl)-1H-indazol-6-yl]-N-ethyl-4-methyl- (CA INDEX NAME)




RN 861904-89-4 CAPLUS

CN Benzamide, N-ethyl-4-methyl-3-[3-[4-(methylsulfonyl)phenyl]-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861904-90-7 CAPLUS

CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(4-methylphenyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861904-91-8 CAPLUS


CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-[4-(trifluoromethyl)phenyl]-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861904-92-9 CAPLUS
 CN Benzamide, 3-[3-(4-chlorophenyl)-1H-indazol-6-yl]-N-ethyl-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-93-0 CAPLUS
 CN Benzamide, N-ethyl-3-fluoro-5-[3-(6-methoxy-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-95-2 CAPLUS
 CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(1-oxido-2-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861904-96-3 CAPLUS

CN Benzamide, N-(1-ethyl-1H-pyrazol-5-yl)-3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861904-97-4 CAPLUS

CN Benzamide, 3-[3-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-indazol-6-yl]-N-ethyl-4-methyl- (CA INDEX NAME)




RN 861904-98-5 CAPLUS

CN Benzamide, 3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 861904-99-6 CAPLUS

CN Benzamide, 3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 861905-00-2 CAPLUS

CN Benzamide, N-ethyl-4-methyl-3-[3-[6-(4-morpholinyl)-3-pyridinyl]-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861905-01-3 CAPLUS

CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(2-pyrimidinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861905-02-4 CAPLUS

CN Benzamide, N-ethyl-4-methyl-3-[3-(5-pyrimidinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861905-03-5 CAPLUS

CN Benzamide, N-ethyl-4-methyl-3-[3-(2-pyrazinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861905-04-6 CAPLUS

CN Benzamide, N-ethyl-3-fluoro-5-[3-(4-fluoro-2-methoxyphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861905-05-7 CAPLUS

CN Benzamide, N-ethyl-3-fluoro-5-[3-(2-methoxy-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861905-06-8 CAPLUS


CN Benzamide, N-ethyl-3-fluoro-5-[3-(4-fluoro-2-methylphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861905-07-9 CAPLUS
 CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(3-pyridinyl)-1H-indazol-6-yl]-
 (CA INDEX NAME)



RN 861905-08-0 CAPLUS
 CN Benzamide, 3-[3-(3,5-dimethyl-4-isoxazolyl)-1H-indazol-6-yl]-N-ethyl-5-
 fluoro-4-methyl- (CA INDEX NAME)




RN 861905-09-1 CAPLUS
 CN 3-Pyridinecarboxamide, N-ethyl-6-[6-[(ethylamino)carbonyl]-2-
 methylphenyl]-1H-indazol-3-yl- (CA INDEX NAME)




RN 861905-10-4 CAPLUS

CN Benzamide, N-(1,4-dimethyl-1H-pyrazol-5-yl)-3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861905-11-5 CAPLUS

CN Benzamide, N-(1,4-dimethyl-1H-pyrazol-5-yl)-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)




RN 861905-12-6 CAPLUS

CN Benzamide, N-(3,5-dimethyl-4-isoxazolyl)-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861905-13-7 CAPLUS

CN Benzamide, 3-[3-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-6-yl]-N-ethyl-5-fluoro-4-methyl- (CA INDEX NAME)




RN 861905-15-9 CAPLUS

CN Formic acid, compd. with N-ethyl-3-fluoro-4-methyl-5-[3-(2-methyl-4-pyridinyl)-1H-indazol-6-yl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861905-14-8

CMF C23 H21 F N4 O



CM 2


CRN 64-18-6

CMF C H2 O2



RN 861905-17-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[(tetrahydro-2-furanyl)methyl]amino]phenyl]-1H-indazol-5-yl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:732643 CAPLUS Full-text
 DOCUMENT NUMBER: 143:193999
 TITLE: Preparation of fused heteroaryl derivatives as p38 kinase inhibitors
 INVENTOR(S): Campos, Sebastien Andre; Swanson, Stephen; Walker, Ann Louise
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073219	A1	20050811	WO 2005-GB281	20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1745038	A1	20070124	EP 2005-702034	20050127
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007519695	T	20070719	JP 2006-550298	20050127
US 20070142372	A1	20070621	US 2006-587614	20060728
PRIORITY APPLN. INFO.:			GB 2004-2140	A 20040130
			WO 2005-GB281	W 20050127

OTHER SOURCE(S): CASREACT 143:193999; MARPAT 143:193999
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring, R1 = Me or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H, cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo] and their pharmaceutically acceptable salts, are prepared and disclosed as p38 kinase inhibitors. Thus, e.g., II was prepared by coupling of N-cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide (preparation given) with 2-(bromomethyl)tetrahydro-2H-pyran. The activity of I was evaluated in fluorescence anisotropy kinase binding assays and it was revealed that compds. of the invention displayed IC50 values of <10 µM or pKi values of >6. I as p38 kinase inhibitor should prove useful in the treatment of disease states mediated by p38 kinase. Pharmaceutical compns. comprising I are disclosed.

IT 861972-61-4P 861972-62-5P 861972-63-8P


861972-66-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)


RN 861972-61-4 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[6-[5-[(ethylamino)carbonyl]-2-methylphenyl]-1H-indazol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 861972-62-5 CAPLUS

CN Benzamide, N-ethyl-4-methyl-3-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




RN 861972-65-8 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[6-[5-[(ethylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 861972-66-9 CAPLUS

CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his nofil

(FILE 'HOME' ENTERED AT 15:02:02 ON 26 NOV 2008)

FILE 'REGISTRY' ENTERED AT 15:03:09 ON 26 NOV 2008
ACT PAGONAKIS790/A

L1 STR
L2 STR
L3 SCR 7 OR 21
L4 331 SEA SSS FUL L3 AND L2 AND L1

FILE 'CAPLUS' ENTERED AT 15:03:44 ON 26 NOV 2008
L5 12 SEA ABB=ON PLU=ON L4
D QUE L4
DIS

FILE 'REGISTRY' ENTERED AT 15:06:53 ON 26 NOV 2008
L6 STR L1
L7 5 SEA SUB=L4 SSS SAM L6
L8 128 SEA SUB=L4 SSS FUL L6

FILE 'CAPLUS' ENTERED AT 15:20:41 ON 26 NOV 2008
L9 4 SEA ABB=ON PLU=ON L8
L10 1 SEA ABB=ON PLU=ON US2006-587790/APPS
L11 0 SEA ABB=ON PLU=ON L9 AND L10
SEL RN L10

FILE 'REGISTRY' ENTERED AT 15:21:11 ON 26 NOV 2008
L12 1 SEA ABB=ON PLU=ON 291782-12-2/BI
D SCA

FILE 'CAPLUS' ENTERED AT 15:21:54 ON 26 NOV 2008
E US2006-587790/APPS
E WO2005-GB265/APPS
L13 1 SEA ABB=ON PLU=ON (WO2005-GB265/AP OR WO2005-GB265/PRN)
SEL RN

FILE 'REGISTRY' ENTERED AT 15:22:34 ON 26 NOV 2008
L14 239 SEA ABB=ON PLU=ON (100-39-0/BI OR 100-63-0/BI OR 1003-03-8/BI
OR 10075-50-0/BI OR 107-10-8/BI OR 108-00-9/BI OR 109-12-6/BI
OR 109-55-7/BI OR 109-73-9/BI OR 109-85-3/BI OR 1194-02-1/BI
OR 128796-39-4/BI OR 130628-75-0/BI OR 139911-29-8/BI OR
14331-56-7/BI OR 149104-88-1/BI OR 151681-01-5/BI OR 16114-47-9

/BI OR 163105-90-6/BI OR 165245-96-5/BI OR 1679-18-1/BI OR
 169124-35-0/BI OR 1692-25-7/BI OR 17874-79-2/BI OR 179899-07-1/
 BI OR 1820-80-0/BI OR 186498-02-2/BI OR 192443-10-0/BI OR
 192443-34-8/BI OR 192443-35-9/BI OR 19847-10-0/BI OR 201733-56-
 4/BI OR 220769-83-5/BI OR 22195-47-7/BI OR 22237-13-4/BI OR
 2516-34-9/BI OR 2516-47-4/BI OR 261953-36-0/BI OR 29939-37-5/BI
 OR 31329-64-3/BI OR 313350-36-6/BI OR 31519-62-7/BI OR
 3218-02-8/BI OR 32637-62-0/BI OR 350-28-7/BI OR 351019-18-6/BI
 OR 3524-49-0/BI OR 352530-44-0/BI OR 3528-58-3/BI OR 368-90-1/B
 I OR 371-40-4/BI OR 38041-19-9/BI OR 39901-94-5/BI OR 402-49-3/
 BI OR 40929-48-4/BI OR 459-46-1/BI OR 4595-61-3/BI OR 4795-29-3/
 /BI OR 4916-55-6/BI OR 504424-71-9/BI OR 504424-72-0/BI OR
 515131-35-8/BI OR 536-89-0/BI OR 53857-57-1/BI OR 541540-09-4/B
 I OR 55401-97-3/BI OR 55458-67-8/BI OR 5720-05-8/BI OR
 574758-37-5/BI OR 585544-30-5/BI OR 589-21-9/BI OR 634187-64-7/
 BI OR 651780-02-8/BI OR 651780-48-2/BI OR 651781-09-8/BI OR
 66572-55-2/BI OR 73870-24-3/BI OR 75-31-0/BI OR 75-65-0/BI OR
 76513-69-4/BI OR 79762-54-2/BI OR 823-85-8/BI OR 86051-75-4/BI
 OR 861904-25-8/BI OR 861904-26-9/BI OR 861904-27-0/BI OR
 861904-28-1/BI OR 861904-29-2/BI OR 861904-30-5/BI OR 861904-31-
 6/BI OR 861904-32-7/BI OR 861904-33-8/BI OR 861904-34-9/BI OR
 861904-35-0/BI OR 861904-36-1/BI OR 861904-37-2/BI OR 861904-38-
 3/BI OR 861904-39-4/BI OR 861904-40-7/BI OR 861904-41-8/BI OR
 861904-42-9/BI OR 861904-43-0/BI OR 861904-44-1/BI OR 861904-45-
 2/BI OR 861904-46-3/BI OR 8

L15 86 SEA ABB=ON PLU=ON L14 AND L8

FILE 'CAPLUS' ENTERED AT 15:23:05 ON 26 NOV 2008

L16 1 SEA ABB=ON PLU=ON L9 AND L13

FILE 'WPIX' ENTERED AT 15:23:17 ON 26 NOV 2008

L17 11 SEA SSS SAM L1 AND L2 AND L6

L18 103 SEA SSS FUL L1 AND L2 AND L6

L19 3 SEA ABB=ON PLU=ON L18/DCR

FILE 'BEILSTEIN' ENTERED AT 15:24:43 ON 26 NOV 2008

L20 0 SEA SSS SAM L1 AND L2 AND L6

L21 0 SEA SSS FUL L1 AND L2 AND L6

FILE 'CAPLUS' ENTERED AT 15:26:14 ON 26 NOV 2008

D QUE L9

FILE 'WPIX' ENTERED AT 15:26:39 ON 26 NOV 2008

D QUE L19

FILE 'CAPLUS, WPIX' ENTERED AT 15:26:47 ON 26 NOV 2008

L22 4 DUP REM L9 L19 (3 DUPLICATES REMOVED)

ANSWERS '1-4' FROM FILE CAPLUS

D L22 IBIB ABS HITSTR TOT